. 2019 Oct 31;4(5):e001825. doi: 10.1136/bmjgh-2019-001825

Table 2.

Cost-effectiveness of childhood cancer treatments

Study	Year	Country	Diagnosis	Inputs included in cost analysis*	Cost per treated patient (2018 USD)	Proportion of patients with 5-year survival	Cost per life saved (2018 USD)	DALYs averted per treated patient using 3% discounting	Cost per DALY averted (2018 USD)	GDP per capita (2017: latest available, USD)
Multiple childhood cancers
Fuentes-Alabi et al ¹⁸	2018	El Salvador	All childhood cancers	Comprehensive	30 035	0.49	61 296	36	1699	3889.31
Renner et al ¹⁶	2018	Ghana	All childhood cancers	Comprehensive	10 540	0.35	30 115	27	1114	2046.11
Leukaemias
Jaime-Perez et al ⁴⁰	2017	Mexico	ALL	Medium	24 788	0.55	45 069	30	1490	8910.33
Gao et al ³¹	2013	China	ALL	Low	27 209	0.50 (5-year EFS)	45 348	30	1505	8826.99
Gu et al ³⁴	2008	China	ALL	Low	44 667	0.67 (5-year EFS)	66 667	30	2213	8826.99
Hayati et al ³⁵	2018	Iran	ALL	Medium	16 914	Not reported	Unable to calculate	QALYs gained per patient (5-year analysis period): 3.78	4475	5593.85
Luo et al ⁴⁶	2008	China	ALL	Medium	18 791	0.78 (7-year EFS)	24 091	30	800	8826.99
Luo et al ⁴⁷	2009	China	APL	Low	24 704	0.38 (3.5-year EFS)	65 011	30	2158	8826.99
Burkitt lymphoma
Denburg et al ³⁰	2019	Uganda	BL	Comprehensive	1401	0.55 (2-year survival)	2574	26	100	606.47
Hesseling et al ³⁷	2003	Malawi	BL	Low	217	0.35 (1-year EFS 0.57 converted to 5-year OS)	620	28	22	338.48
Other
Stefan and Stones ⁵²	2009	South Africa	HL	Low	7360	0.76	9684	28	346	6151.08
Waddell et al ⁵⁴	2015	Uganda	Retinoblastoma	Low	1079	0.37	2916	20	146	606.47

*Comprehensive: ≥10 inputs, Medium: 5–9 inputs, Low: <5 inputs.

ALL, acute lymphoblastic leukaemia; APL, acute promyelocytic leukaemia; BL, Burkitt lymphoma; DALY, disability-adjusted life year; EFS, event-free survival; GDP, gross domestic product; HL, Hodgkin lymphoma; OS, overall survival; QALY, quality-adjusted life year.